Herbal composition and method of use for the treatment of cancer
The invention describes a nutraceutical composition and method for preventing/treating cancer or augmenting chemotherapy in advanced stage malignancies; comprised of [1] tumoricidal herbs; beth root, galbanum, gromwell root, wild yam, balm of gilead bud, frankincense, [2] an antiproliferative herb; speranskia [3] a natural lactic acid dehydrogenase (LDH) inhibitor, 2′,3,4′5,7-pentahydroxyflavone or cinnamon, [4] alkalizing agents: calcium, magnesium, potassium or bicarbonate salts, barley grass, chlorella and spirulina [5] at least one quinone and [6] at least one agent capable of maximizing oxidative mitochondrial function preferably riboflavin, 6,7-Dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin and a pharmaceutically acceptable carrier.
1. A pharmaceutical composition useful for treating or reducing the risk of cancer comprising:
a) frankincense ( Boswellia carteri )
b) at least one tumoricidal agent selected from the group consisting of beth root ( Trillium pendulum root), galbanum ( Ferula galbaniflua ), and wild yam ( Dioscorea villosa ),
c) at least one anti-proliferative herb comprising speranskia herb ( Speranskia tuberculata ) and;
d) at least one lactic acid dehydrogenase inhibitor herein termed “LDH (−)” comprising at least one of cinnamon ( Cinnamomum cassia ) or 2′,3,4′,5,7-pentahydroxyflavone (morin), and
e) a pharmaceutically acceptable carrier
wherein the total amount of component a) is 5-20% by wt of the total composition, the total amount of component b) is 5-20% by wt of the total composition, and wherein component c) is present in a total amount of up to 8% by wt of the total composition.
2. The composition according to claim 1 , wherein said pharmaceutically acceptable carrier comprises one or more selected from the group consisting of water, saline, starches, sugars, gels, lipids, waxes, glycerol, solvents, oils, liquids, proteins, glycols, electrolyte solutions, alcohols, stabilizers, fillers, binders, emulsifiers, humectants, preservatives, buffers, colorants, emollients, foaming agents, sweeteners, thickeners, surfactants, additives, solvents, and mixtures thereof.
3. The composition according to claim 2 , wherein said pharmaceutically acceptable carrier is suitable for oral, external, or injectable administration and is in the form of a solid, liquid, powder, paste, gel, tablet, granule, foam, pack, aerosol, solvent, diluent, capsule, pill, drink, tea, liposome, syrup, solution, suppository, emulsion, enema, suspension, dispersion, food, or mixtures thereof.
4. The composition according to claim 1 wherein the total amount of said LDH (−) is 5-15% by wt of the total composition.
5. The composition of claim 1 wherein said LDH (−) further comprises one or more selected from the group consisting of gromwell root ( Lithospermum erythrorhizon root), epigallocatechin gallate, quercetin, rosemary ( Rosmarinus officinalis ), citric acid, black walnut ( Juglans nigra ), clove ( Syzygium aromaticum ), nutmeg ( Myristica fragans ), licorice root ( Glycyrrhiza glabra ), coriander ( Coriandrum sativum ), ginger root ( Zingiber officinale ), myrrh gum ( Commiphora molmol ), and green tea ( Camellia sinensis ).
6. The composition of claim 1 wherein said tumoricidal agent further comprise one or more selected from the group consisting of teasel root ( Dipsacus asper ), bakuchi seed ( Cyamopsis psoralioides ), kanta kari ( Solanum xanthocarpum ), bushy knotweed rhizome ( Polygonum cuspidatum ), garcinia fruit ( Garcinia cambogia ), white sage ( Salvia apiana ), balm of gilead bud ( Populus balsamifera ), gambogic acid, and diosmin.
7. A method of inhibiting metastasis of cancer in a host, the method comprising administering to a host in need of cancer treatment an amount of the composition of claim 1 effective to inhibit metastasis of the cancer.